Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Musculoskeletal involvement in scleroderma.

Janet E Pope1

  • 1Division of Rheumatology, Department of Medicine, The University of Western Ontario, Canada. janet.pope@sjhc.london.on.ca

Rheumatic Diseases Clinics of North America
|July 5, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CDAI trajectories in patients with rheumatoid arthritis treated with abatacept in real-world.

Advances in rheumatology (London, England)·2026
Same author

Lessons from an early rheumatoid arthritis incident cohort.

Seminars in arthritis and rheumatism·2026
Same author

Evaluating machine learning tools to assist title and abstract screening in systematic literature reviews: a report based on the EULAR RA Management Recommendations Task Force.

Annals of the rheumatic diseases·2026
Same author

Racial minorities are under-represented in SLE clinical trials: A systematic review and meta-analysis.

Autoimmunity reviews·2026
Same author

Real-World Upadacitinib Persistence and Clinical Outcomes Among Canadian Patients with Inflammatory Arthritis from a Patient Support Program: The UPRAISE Study.

Rheumatology and therapy·2026
Same author

Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis.

Annals of the rheumatic diseases·2026
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Scleroderma frequently causes musculoskeletal issues like joint pain and arthritis, significantly impacting patient morbidity. Current treatments for these symptoms lack strong evidence from randomized controlled trials.

Area of Science:

  • Rheumatology
  • Immunology
  • Orthopedics

Background:

  • Scleroderma is a connective tissue disease with diverse clinical manifestations.
  • Musculoskeletal symptoms, including arthralgias, inflammatory arthritis, and myopathy, are common in scleroderma.
  • These symptoms contribute significantly to patient morbidity and disability.

Purpose of the Study:

  • To review the spectrum of musculoskeletal manifestations in scleroderma.
  • To discuss the diagnostic and therapeutic challenges associated with these symptoms.
  • To highlight the need for evidence-based treatment strategies.

Main Methods:

  • Literature review of musculoskeletal manifestations in scleroderma.
  • Analysis of associated autoimmune conditions and autoantibodies.

Related Experiment Videos

  • Evaluation of current treatment approaches and evidence base.

    • Main Results:

    • Scleroderma presents with arthralgias, inflammatory arthritis, contractures, nerve entrapment, myositis, and myopathy.
    • Overlap syndromes with Sjogren's syndrome, lupus, and rheumatoid arthritis are recognized.
    • Many treatments for musculoskeletal symptoms are symptomatic and lack randomized controlled trial validation.

    Conclusions:

    • Musculoskeletal manifestations are a primary source of disability in scleroderma.
    • There is a critical need for rigorously tested treatments for these debilitating symptoms.
    • Further research is essential to improve the management of scleroderma-related musculoskeletal conditions.